MX2010005198A - Composiciones liquidas que comprenden valsartan. - Google Patents

Composiciones liquidas que comprenden valsartan.

Info

Publication number
MX2010005198A
MX2010005198A MX2010005198A MX2010005198A MX2010005198A MX 2010005198 A MX2010005198 A MX 2010005198A MX 2010005198 A MX2010005198 A MX 2010005198A MX 2010005198 A MX2010005198 A MX 2010005198A MX 2010005198 A MX2010005198 A MX 2010005198A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions
methods
valsartan
pediatric
Prior art date
Application number
MX2010005198A
Other languages
English (en)
Inventor
Joseph Lawrence Zielinski
Robert Frank Wagner
Wayne Talamonti
Gregory Harasymiw
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010005198A publication Critical patent/MX2010005198A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones que comprenden soluciones acuosas de valsartán adecuadas para administración oral, preferiblemente en poblaciones pediátrica y geriátrica. Se proporcionan métodos para preparar tales composiciones y métodos para su estabilización.
MX2010005198A 2007-11-12 2008-11-10 Composiciones liquidas que comprenden valsartan. MX2010005198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98717807P 2007-11-12 2007-11-12
PCT/US2008/082932 WO2009064681A2 (en) 2007-11-12 2008-11-10 Liquid compositions comprising valsartan

Publications (1)

Publication Number Publication Date
MX2010005198A true MX2010005198A (es) 2010-05-20

Family

ID=40639403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005198A MX2010005198A (es) 2007-11-12 2008-11-10 Composiciones liquidas que comprenden valsartan.

Country Status (10)

Country Link
US (2) US20100267787A1 (es)
EP (2) EP2316422A1 (es)
JP (1) JP2011503105A (es)
KR (1) KR20100087002A (es)
CN (1) CN101854913A (es)
BR (1) BRPI0820198A2 (es)
CA (1) CA2705453A1 (es)
MX (1) MX2010005198A (es)
RU (2) RU2488393C2 (es)
WO (1) WO2009064681A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278099B2 (en) 2011-10-31 2016-03-08 Novartis Ag Pazopanib formulation
WO2013098268A2 (en) * 2011-12-26 2013-07-04 Novartis Ag Tablets and dry-coated agents
ES2584248B1 (es) * 2015-03-24 2017-04-19 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral
CN105596305A (zh) * 2015-12-25 2016-05-25 华润赛科药业有限责任公司 一种高稳定性的缬沙坦制剂及其制备方法
WO2017191619A2 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A process for the preparation of a salt of sacubitril and valsartan
WO2018204040A1 (en) * 2017-05-01 2018-11-08 Bioramo, Llc Oral liquid compositions of valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10548838B1 (en) 2018-12-14 2020-02-04 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) * 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19675036I2 (de) 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
JP4102664B2 (ja) 2000-07-19 2008-06-18 ノバルティス アクチエンゲゼルシャフト バルサルタン塩
HUP0500843A2 (hu) * 2001-12-20 2005-12-28 Bristol-Myers Squibb Co., Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
EP1691788A2 (en) * 2003-11-21 2006-08-23 Schering Corporation Phosphodiesterase v inhibitor formulations
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP2197416A1 (en) * 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan

Also Published As

Publication number Publication date
WO2009064681A3 (en) 2009-10-08
CA2705453A1 (en) 2009-05-11
US20100267787A1 (en) 2010-10-21
RU2013101018A (ru) 2014-07-20
KR20100087002A (ko) 2010-08-02
RU2488393C2 (ru) 2013-07-27
JP2011503105A (ja) 2011-01-27
EP2222273A2 (en) 2010-09-01
CN101854913A (zh) 2010-10-06
EP2316422A1 (en) 2011-05-04
BRPI0820198A2 (pt) 2019-09-24
US20130109729A1 (en) 2013-05-02
WO2009064681A2 (en) 2009-05-22
RU2010123691A (ru) 2011-12-20
AU2008321159A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
IL202379A (en) Benzoxaborols, their pharmaceutical preparations and their use in the preparation of bacteria to inhibit the growth of germs
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL199945A (en) Hydrochloric acid derivatives, pharmaceuticals containing them and their use in the preparation of drugs
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
EP3626253A3 (en) Stable formulations of linaclotide
IL200206A (en) The history of quinaxaline, their preparation and their pharmaceutical preparations
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
MX2009013501A (es) Compuestos piperidinicos y sus usos.
IL207972A (en) History of pyridine-2-ram, pharmaceuticals containing them and their use in the preparation of medicines
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
GB0615105D0 (en) Novel compounds
WO2009113091A3 (en) Pharmaceutical compositions comprising valsartan
ZA201005316B (en) 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them
GB0620619D0 (en) Novel compounds
TN2015000156A1 (en) Dispersible tablet